Suzhou CureMed Biopharma Technology Co., Ltd
PrivateLast Round
Series C
May 16, 2025
Est. Valuation
$416.36M
Total Funding Raised
$20.88M
Company Overview
Suzhou CureMed Biopharma Technology Co., Ltd operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series C round in May 2025.
Suzhou CureMed Biopharma Technology Co., Ltd is a biopharmaceutical company that develops circular mRNA nucleic acid drugs and LNP delivery systems for infectious diseases, oncology, and gene therapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Suzhou CureMed Biopharma Technology Co., Ltd Comparables
Compare Suzhou CureMed Biopharma Technology Co., Ltd with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RiboX Therapeutics | 87% | |
| Byterna Therapeutics | 87% | |
| Therorna Inc. | 87% |
For institutional investors. Book with your work email.
Suzhou CureMed Biopharma Technology Co., Ltd Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 16, 2025 | ||||
| Strategic | Apr 27, 2025 | ||||
| Series B | Apr 2, 2024 | ||||
| Series A | May 27, 2022 |
For institutional investors. Book with your work email.
Suzhou CureMed Biopharma Technology Co., Ltd Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shenzhen New Industry Venture Capital | Series B |
| Bin Zayed Group | Strategic |
| HongShan Capital Group (HSG) | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2025
$21M round completed.
- Apr 27, 2025
Bin Zayed Group led the strategic round.
For institutional investors. Book with your work email.
Suzhou CureMed Biopharma Technology Co., Ltd Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Suzhou CureMed Biopharma Technology Co., Ltd's valuation, stock price, and market status.
Is Suzhou CureMed Biopharma Technology Co., Ltd a public or private company?
Suzhou CureMed Biopharma Technology Co., Ltd is a private company.
What is the current stock price of Suzhou CureMed Biopharma Technology Co., Ltd?
Suzhou CureMed Biopharma Technology Co., Ltd is a private company, so its shares have no public market price. Caplight tracks Suzhou CureMed Biopharma Technology Co., Ltd's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Suzhou CureMed Biopharma Technology Co., Ltd worth (valuation)?
Suzhou CureMed Biopharma Technology Co., Ltd's valuation is estimated at $416.4M based on funding round data.
Can I buy Suzhou CureMed Biopharma Technology Co., Ltd stock?
Suzhou CureMed Biopharma Technology Co., Ltd shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Suzhou CureMed Biopharma Technology Co., Ltd's last funding round?
Suzhou CureMed Biopharma Technology Co., Ltd's most recent funding round was Series C on May 16, 2025.
Who are the main investors in Suzhou CureMed Biopharma Technology Co., Ltd?
Key investors in Suzhou CureMed Biopharma Technology Co., Ltd include Bin Zayed Group, HongShan Capital Group (HSG).
Will Suzhou CureMed Biopharma Technology Co., Ltd IPO soon?
No public IPO plans have been announced for Suzhou CureMed Biopharma Technology Co., Ltd.
How can I track Suzhou CureMed Biopharma Technology Co., Ltd secondary market activity?
Caplight tracks bids, offers, and trades in Suzhou CureMed Biopharma Technology Co., Ltd's shares on secondary markets.